Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologymhn Inlexzo (gemcitabine) Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedmhnPolicy CP.PHAR.753

    Clinical Policy: Gemcitabine Intravesical System (Inlexzo)

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.753 alerts

    Get alerted when Policy CP.PHAR.753 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization criteria for Inlexzo (gemcitabine intravesical system) for treatment of BCG-unresponsive non-muscle invasive bladder cancer and related coverage rules for affected members and providers.

    Policy Summary
    Payermhn
    PolicyClinical Policy: Gemcitabine Intravesical System (Inlexzo)
    Policy CodePolicy CP.PHAR.753
    Change TypeMaterial: coding and documentation requirements added (J9183 addedAdstiladrin attestation required)
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionPrior authorization is required and providers must submit documentation including an attestation that Adstiladrin therapy was considered and not recommended with clinical rationale.
    SourceLink
    POLICY UPDATE CHANGES

    Provider attestation that Adstiladrin® therapy has been considered and not recommended (provider must submit clinical rationale supporting use of Inlexzo over Adstiladrin) is required.

    HCPCS code J9183 (Gemcitabine intravesical system, 225 mg) was added and codes J3590 and C9399 were removed.

    ICHRA (health insurance marketplace/ICHRA) line of business was added to the policy.

    225 mgsingle-dose product availability
    8 then 6FDA-approved dosing regimen

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsapproval duration
    J9183HCPCS code for product
    2Codes removed

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    BCG-unresponsive NMIBC initial approval: 1. Diagnosis of non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS); 2. Prescribed by or in consultation with an oncologist or urologist; 3. Patient age ≥ 18 years; 4. Member is refractory to BCG treatment (see Appendix D); 5. Member is not a candidate for cystectomy; 6. Member has previously undergone transurethral resection of bladder tumor (TURBT); 7. Provider attestation that Adstiladrin® therapy has been considered and not recommended, with clinical rationale supporting use of Inlexzo over Adstiladrin; 8. Request meets one of the following: a) Dose does not exceed 225 mg once every 3 weeks for 8 instillations followed by once every 12 weeks for 6 instillations; OR b) Dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

    Approval duration: 12 months

    Continuation Therapy

    Covered when ALL of the following are met:

    BCG-unresponsive NMIBC continued therapy: 1. Member is currently receiving Inlexzo via the Plan benefit, or documentation supports the member has received Inlexzo for a covered indication for at least 30 days; 2. Member is responding positively to therapy as evidenced by lack of disease recurrence or progression; 3. Member has not received ≥ 14 instillations; 4. If the request is for a dose increase, the request meets one of the following: a) If member has received < 8 instillations: new dose does not exceed 225 mg once every 3 weeks for up to 8 total instillations followed by once every 12 weeks for 6 instillations; b) If member has received ≥ 8 instillations: new dose does not exceed 225 mg once every 12 weeks for up to 6 total instillations; c) New dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence).

    Approval duration: 12 months

    Other Indications / Off-label Handling

    If use is not listed under covered indications:

    Other indications handling: 1. If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, follow the listed formulary/no‑coverage or non‑formulary policies for the relevant line of business as specified in the policy; 2. If the requested use (diagnosis, age, dosing regimen) is not specifically listed under section III and criterion 1 does not apply, refer to the off‑label use policy for the relevant line of business (see referenced line‑of‑business off‑label policies).

    See related policies CP.CPA.190, HIM.PA.103/HIM.PA.154, CP.PMN.16/CP.PMN.53 for details

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation demonstrating efficacy and safety in accordance with the applicable off‑label use policy. Applicable off‑label policies include CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace/ICHRA), and CP.PMN.53 (Medicaid), or other evidence of coverage documents as applicable.

    When state Medicaid coverage provisions conflict with the requirements or coverage provisions in this clinical policy, the state Medicaid provisions take precedence. Providers should consult the applicable state Medicaid manual for any state‑specific coverage rules that apply to Medicaid members.

    Requests for diagnoses or indications that are non‑FDA approved and that lack sufficient documentation of efficacy and safety per the applicable off‑label use policies are considered not authorized and may be denied. Providers must follow the referenced off‑label policies (for the member's line of business) and submit supporting clinical evidence when requesting coverage for off‑label use.

    Coding and Billing

    Covered HCPCS CodesHCPCSCovered
    J9183Gemcitabine intravesical system, 225 mg
    Removed/obsolete codesHCPCS
    J3590Unclassified drug or biologic (removed)
    C9399Unclassified drugs or biologics (removed)
    Referenced HCPCS Codes and revisionsHCPCS
    J9183Gemcitabine intravesical system, 225 mg
    J3590
    C9399
    inv-10: Maximum instillations
    Maximum total instillationsUp to 14 total instillations (8 once every 3 weeks, then 6 once every 12 weeks)
    Induction phase225 mg inserted into the bladder once every 3 weeks for 8 instillations
    Maintenance phase225 mg once every 12 weeks for 6 instillations
    Dose limitDose does not exceed 225 mg per instillation for the 8+6 regimen

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required — 12‑month approvals

    Prior authorization is required for Inlexzo (J9183); when the approval criteria for initial or continued therapy are met, authorization is granted for 12 months.

    Billing Rule

    Use J9183 for Inlexzo and follow PA process

    Use HCPCS code J9183 (Gemcitabine intravesical system, 225 mg) when requesting coverage for Inlexzo and follow the Health Plan’s prior authorization processes for this code; include any required attestation about consideration of Adstiladrin when submitting the request.

    Background

    Inlexzo (gemcitabine intravesical system) is an intravesical formulation of gemcitabine indicated for adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The product is intended for intravesical instillation per the prescribing information; use for indications not within the FDA‑approved labeling requires off‑label documentation per the applicable off‑label policies.

    Definitions

    inv-21: BCG-unresponsive (refractory)
    Definition of BCG-unresponsive (refractory)Persistent or recurrent CIS alone or with recurrent Ta/T1 disease within 12 months of adequate BCG therapy
    Adequate BCG therapy — option AAt least 5 or 6 doses of an initial induction course plus 2 of 3 doses of maintenance therapy
    Adequate BCG therapy — option BAt least 5 or 6 doses of an initial induction course plus at least 2 of 6 doses of a second induction course
    Reference for requirementSee Appendix D for full BCG-unresponsive definition; prior authorization for BCG immunotherapy may be required
    inv-22: CIS
    TermCIS (carcinoma in-situ)
    Policy Summary
    Payermhn
    PolicyClinical Policy: Gemcitabine Intravesical System (Inlexzo)
    Policy CodePolicy CP.PHAR.753
    Change TypeMaterial: coding and documentation requirements added (J9183 addedAdstiladrin attestation required)
    Effective DateDec 1, 2025
    Next Review Date
    Key ActionPrior authorization is required and providers must submit documentation including an attestation that Adstiladrin therapy was considered and not recommended with clinical rationale.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and Documentation RequirementsBackgroundDefinitions
    Step Therapy

    BCG step — refractory requirement

    Prior authorization for BCG immunotherapy may be required; member must be refractory to BCG as defined in Appendix D (BCG‑unresponsive) to meet initial therapy criteria.

    • BCG prior authorization may be required
    • Member must meet the policy definition of BCG‑unresponsive per Appendix D
    Prior Authorization

    Document consideration of Adstiladrin

    Document in the prior authorization request that alternative intravesical therapy Adstiladrin was considered and not recommended; include clinical rationale explaining why Adstiladrin is not appropriate and Inlexzo is being requested instead.

    Documentation Required

    Submit supportive clinical documentation

    Submit clinical documentation (such as office chart notes, lab results, TURBT records, and other relevant clinical information) demonstrating the member meets all approval criteria for Inlexzo.

    • Evidence of prior TURBT and BCG‑refractory status
    • Clinical notes showing indication (NMIBC with CIS) and prescriber specialty
    • Objective evidence of response for continuation requests
    Documentation Required

    Attestation: Adstiladrin considered and not recommended

    Include a signed provider attestation that Adstiladrin® therapy has been considered and not recommended, and provide the clinical rationale supporting use of Inlexzo over Adstiladrin as part of the prior authorization submission.

    Documentation Required

    Include required documentation and attestation with J9183 requests

    When requesting coverage for J9183, submit documentation supporting medical necessity for the Gemcitabine intravesical system and include the required provider attestation regarding Adstiladrin consideration per the policy revisions.

    • Clinical evidence supporting dosing and prior treatments
    • Provider attestation addressing Adstiladrin consideration and rationale
    Denial Risk

    Denial risk for non‑FDA approved indications without adequate evidence

    Requests for non‑FDA approved (off‑label) indications that lack sufficient documentation of efficacy and safety per the applicable off‑label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) may be denied.

    • If the use is not listed under the policy, follow the referenced off‑label use policy for the applicable line of business
    Note

    Coding inclusion/exclusion does not guarantee coverage

    Inclusion or exclusion of codes in this policy does not guarantee coverage; providers must reference the most up‑to‑date professional coding guidance prior to claim submission.

    AbbreviationCIS = carcinoma in-situ
    ContextReferenced as the histologic indication for Inlexzo use in NMIBC criteria
    inv-23: Inlexzo PI
    Reference documentInlexzo Prescribing Information (Inlexzo PI) cited in policy references
    Source detailsHorsham, PA: Janssen Biotech Inc.; September 2025. Available at: www.inlexzo.com (Accessed September 17, 2025)
    Use in policyPrescribing information used as a primary reference for dosing and indication statements
    inv-24: TAR-200
    Clinical study referenceTAR-200 is referenced in the SunRISe-1 study for BCG-unresponsive high-risk NMIBC (Daneshmand et al., J Clin Oncol. 2025)
    Citation detailsDaneshmand S, Van der Heijden MS, Jacob JM, et al. TAR-200 for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Results from the phase IIb SunRISe-1 study. J Clin Oncol. 2025 Jul 30:JCO2501651.
    Role in policyListed among references in Section VII and cited as related clinical evidence